LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the United States Patent & Trademark Office (USPTO) has issued US Pat. No. 10,758,567 B2, titled “IN VIVO PRIMING OF NATURAL KILLER CELLS,” which covers a method for treating cancer using INKmune™, a natural killer (NK) cell priming technology. The patent expires in 2036.
News
INmune Bio Co-Founder and CEO Presents at Maxim Group?s Conference on Alzheimer?s Disease
LA JOLLA, Calif., July 03, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc.?(NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, announced that R.J. Tesi, M.D., the company?… […]
News
INmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member
LA JOLLA, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, is pleased to announce that Edgardo (Ed) Bar… […]
News
INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option
LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, toda… […]
